Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.5623
+0.0123 (2.24%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
2.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
| Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
| Dec 31, 2021 | 86.99K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 939.93K | -92.31K | -8.94% |
| Dec 31, 2013 | 1.03M | -299.53K | -22.49% |
| Dec 31, 2012 | 1.33M | -112.68K | -7.80% |
| Dec 31, 2011 | 1.44M | 135.54K | 10.35% |
| Dec 31, 2010 | 1.31M | 667.63K | 104.11% |
| Dec 31, 2009 | 641.29K | 407.75K | 174.59% |
| Dec 31, 2008 | 233.54K | 100.45K | 75.48% |
| Dec 31, 2007 | 133.09K | 66.91K | 101.11% |
| Dec 31, 2006 | 66.18K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 5.07M |
| 60 Degrees Pharmaceuticals | 1.41M |
| Scinai Immunotherapeutics | 1.31M |
| SciSparc | 1.31M |
| PMGC Holdings | 590.08K |
OGEN News
- 8 days ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire
- 22 days ago - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - GlobeNewsWire
- 23 days ago - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - GlobeNewsWire
- 24 days ago - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia - GlobeNewsWire
- 7 weeks ago - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - GlobeNewsWire
- 2 months ago - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - GlobeNewsWire
- 5 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 5 months ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire